肝肾综合征临床诊断标准的变迁及新的肾损伤指标在肝硬化患者中的应用

刘沁雨; 李海

doi:10.3969/j.issn.1001-5256.2018.06.038

肝肾综合征临床诊断标准的变迁及新的肾损伤指标在肝硬化患者中的应用

DOI: 10.3969/j.issn.1001-5256.2018.06.038

刘沁雨,
李海

中国人民武装警察后勤学院附属医院肝胆胰脾科

详细信息

中图分类号: R575;R692.5
计量
- 文章访问数: 1848
- HTML全文浏览量: 43
- PDF下载量: 390
- 被引次数: 0
出版历程
- 收稿日期: 2017-12-06
- 出版日期: 2018-06-20

Changes in diagnostic criteria for hepatorenal syndrome and the application of new renal injury indices in cirrhotic patients

Liu QinYu,
Li Hai

Department of Hepatopancreatobiliary and Splenic Medicine, Affiliated Hospital of Logistics University of Chinese People's Armed Police Forces

摘要

摘要: 肝肾综合征是一种严重的失代偿期肝硬化并发症,短期病死率极高。目前尚缺乏有效的内科治疗方法,一些药物尽管有效,但其报道的疗效不一,原因之一是诊断标准并不统一。介绍了肝肾综合征诊断标准的变迁和新的肾损伤指标或方法,指出一个统一的诊断标准将成为肝肾综合征临床研究的基础,也有利于临床医生进一步认识此严重的肝硬化并发症。
- 肝肾综合征 /
- 诊断 /
- 综述
Abstract: Hepatorenal syndrome is a serious complication of decompensated cirrhosis and has high short-term mortality. There still lacks effective medical treatment at present. Although some drugs are effective, but their effects reported in the literature were different due to a lack of uniform diagnostic criteria. This article introduces the changes in the diagnostic criteria for hepatorenal syndrome and points out that uniform diagnostic criteria will become the basis for clinical research on hepatorenal syndrome and may also help clinicians to understand this serious complication of liver cirrhosis.
- hepatorenal syndrome /
- diagnosis /
- review

HTML全文

参考文献(33)

[1]SONG TX, QI XS, GAO F, et al.Advances in diagnosis and treatment of hepatorenal syndrome type of acute kidney injury in patients with liver cirrhosis[J].J Clin Hepatol, 2017, 33 (3) :572-576. (in Chinese) 宋廷雪, 祁兴顺, 高帆, 等.肝硬化肝肾综合征型急性肾损伤的诊治进展[J].临床肝胆病杂志, 2017, 33 (3) :572-576.

[2]BELCHER JM, COCA SG, PARIKH CR.Creatinine change on vasoconstrictors as mortality surrogate in hepatorenal syndrome:Systematic review&Meta-analysis[J].PLo S One, 2015, 10 (8) :e0135625.

[3]GLASS L, SHARMA P.Evidence-based therapeutic options for hepatorenal syndrome[J].Gastroenterology, 2016, 150 (4) :1031-1033.

[4]WONG F, LEUNG W, AL BM, et al.Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation[J].Liver Transpl, 2015, 21 (3) :300-307.

[5]YAP DY, SETO WK, FUNG J, et al.Serum and urinary biomarkers that predict hepatorenal syndrome in patients with advanced cirrhosis[J].Dig Liver Dis, 2017, 49 (2) :202-206.

[6]RLY B, CAREY WD, KAPOOR B, et al.Hepatorenal syndrome:A review of pathophysiology and current treatment options[J].Semin Intervent Radiol, 2015, 32 (4) :445-454.

[7]ENESCU A, PETRESCU F, MITRUT P, et al.Hepatorenal syndrome:Diagnosis and treatment-newsreel[J].Rom J Intern Med, 2016, 54 (3) :143-150.

[8]TAPPER EB, BONDER A, CARDENAS A.Preventing and treating acute kidney injury among hospitalized patients with cirrhosis and ascites:A narrative review[J].Am J Med, 2016, 129 (5) :461-467.

[9]XIONG HF, LIU JY.Research progress on hepatorenal syndrome[J/CD].Chin J Liver Dis:Electronic Edition, 2017, 9 (1) :1-6. (in Chinese) 熊号峰, 刘景院.肝肾综合征研究进展[J/CD].中国肝脏病杂志:电子版, 2017, 9 (1) :1-6.

[10]WANG JB.Pathophysiological basis of portal hypertension and the new concept of acute kidney injury in patients with liver cirrhosis[J].Chin J Hepatol, 2017, 25 (6) :408-410. (in Chinese) 王江滨.门静脉高压的发生基础及肝硬化急性肾损伤的新概念[J].中华肝脏病杂志, 2017, 25 (6) :408-410.

[11]GIFFORD FJ, MORLING JR, FALLOWFIELD JA.Systematic review with meta-analysis:Vasoactive drugs for the treatment of hepatorenal syndrome type 1[J].Aliment Pharmacol Ther, 2017, 45 (5) :593-603.

[12]SANYAL AJ, BOYER TD, FREDERICK RT, et al.Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs.placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies[J].Aliment Pharmacol Ther, 2017, 45 (11) :1390-1402.

[13]ZHANG Y, HU GQ, LIU P, et al.Research progress on the treatment of hepatorenal syndrome[J/CD].Chin J Liver Dis:Electronic Edition, 2017, 9 (3) :26-29. (in Chinese) 张彦, 胡国启, 刘萍, 等.肝肾综合征治疗的研究进展[J/CD].中国肝脏病杂志:电子版, 2017, 9 (3) :26-29.

[14]CAI CX, MADDUKURI G, JAIPAUL N, et al.A treat-to-target concept to guide the medical management of hepatorenal syndrome[J].Dig Dis Sci, 2015, 60 (5) :1474-1481.

[15]OKAMURA Y, HATA K, INAMOTO O, et al.Influence of hepatorenal syndrome on outcome of living donor liver transplantation:A single-center experience in 357 patients[J].Hepatol Res, 2017, 47 (5) :425-434.

[16]ACEVEDO JG, CRAMP ME.Hepatorenal syndrome:Update on diagnosis and therapy[J].World J Hepatol, 2017, 9 (6) :293-299.

[17]ZHANG LL, LI L, JI GX, et al.The value of serum Cys C in diagnosis of subclinical hepatorenal syndrome[J].Chin J Gastroenterol Hepatol, 2017, 26 (1) :25-28. (in Chinese) 张利利, 李莉, 纪桂贤, 等.血清Cys C在亚临床肝肾综合征中的诊断价值[J].胃肠病学和肝病学杂志, 2017, 26 (1) :25-28.

[18]WANG D, FENG JF, WANG AQ, et al.Role of Cystatin C and glomerular filtration rate in diagnosis of kidney impairment in hepatic cirrhosis patients[J].Medicine, 2017, 96 (20) :e6949.

[19]UGUEN T, JEZEQUEL C, ROPERT M, et al.Pretransplant renal function according to CKD-EPI cystatin C equation is a prognostic factor of death after liver transplantation[J].Liver Int, 2016, 36 (4) :547-554.

[20]STAYNER C, POOLE CA, MCGLASHAN SR, et al.An ovine hepatorenal fibrocystic model of a Meckel-like syndrome associated with dysmorphic primary cilia and TMEM67 mutations[J].Sci Rep, 2017, 7 (1) :1601.

[21]MINDIKOGLU AL, PAPPAS SC.New developments in hepatorenal syndrome[J].Clin Gastroenterol Hepatol, 2018, 16 (2) :162-177.

[22]KARVELLAS CJ, DURAND F, NADIM MK.Acute kidney injury in cirrhosis[J].Crit Care Clin, 2015, 31 (4) :737-750.

[23]JI GX, GAO FL, FU LK, et al.The significance of serum Cys C andβ2-MG combined with urineα1-MG andβ2-MG on hepatorenal syndrome diagnosis[J].Chin J Gastroenterol Hepatol, 2017, 26 (7) :802-804. (in Chinese) 纪桂贤, 高福来, 付丽坤, 等.血清Cys C、β2-MG联合尿α1-MG、β2-MG在亚临床肝肾综合征诊断中的意义[J].胃肠病学和肝病学杂志, 2017, 26 (7) :802-804.

[24]CHEN YF, ZHANG YB, LIANG CQ.An analysis of predictive factors for concurrent acute-on-chronic liver failure and hepatorenal syndrome[J].J Clin Hepatol, 2015, 31 (9) :1422-1425. (in Chinese) 陈艳芳, 张永标, 梁彩倩.慢加急性肝衰竭并发肝肾综合征的预测因素分析[J].临床肝胆病杂志, 2015, 31 (9) :1422-1425.

[25]GTZBERGER M, KAISER C, LANDAUER N, et al.Intrarenal resistance index for the assessment of early renal function impairment in patients with liver cirrhosis[J].Eur J Med Res, 2008, 13 (8) :383-387.

[26]LOW G, ALEXANDER GJ, LOMAS DJ.Hepatorenal syndrome:Aetiology, diagnosis, and treatment[J].Gastroenterol Res Pract, 2015, 2015:207012.

[27]MOCARZEL L, LANZIERI P, NASCIMENTO J, et al.Hepatorenal syndrome with cirrhotic cardiomyopathy:Case report and literature review[J].Case Reports Hepatol, 2015, 2015:573513.

[28]LOW G, ALEXANDER GJ, LOMAS DJ.Renal impairment in cirrhosis unrelated to hepatorenal syndrome[J].Can J Gastroenterol Hepatol, 2015, 29 (5) :253-257.

[29]HEIDEMANN J, BARTELS C, BERSSENBRUGGE C, et al.Hepatorenal syndrome:Outcome of response to therapy and predictors of survival[J].Gastroenterol Res Pract, 2015, 2015:457613.

[30]LI H, HAN T, LI Y, et al.The early renal injury and its related factors in patients with chronic HBV infection[J].Chin J Blood Purificat, 2015, 14 (11) :644-648. (in Chinese) 李海, 韩涛, 李岩, 等.慢性乙型肝炎病毒感染患者肾功能早期损伤指标变化及其影响因素[J].中国血液净化, 2015, 14 (11) :644-648.

[31]SOBHONSLIDSUK A.Current position of vasoconstrictor and albumin infusion for type 1 hepatorenal syndrome[J].World J Gastrointest Pharmacol Ther, 2015, 6 (3) :28-31.

[32]ALLEGRETTI AS, ORTIZ G, WENGER J, et al.Prognosis of acute kidney injury and hepatorenal syndrome in patients with cirrhosis:A prospective cohort study[J].Int J Nephrol, 2015, 2015:108139.

[33]DAVENPORT A, SHEIKH MF, LAMB E, et al.Acute kidney injury in acute-on-chronic liver failure:Where does hepatorenal syndrome fit?[J].Kidney Int, 2017, 92 (5) :1058-1070.

施引文献

资源附件(0)

访问统计